Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aprea Therapeutics, Inc. (Nasdaq: APRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Aprea files reports with the U.S. Securities and Exchange Commission as a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol APRE.
Among the key documents available through EDGAR are Aprea’s Form 8-K current reports, which the company uses to furnish earnings press releases, clinical program updates, financing announcements, and changes to its corporate presentation slide decks. For example, recent 8-K filings reference quarterly financial results, clinical updates from the ACESOT-1051 WEE1 inhibitor trial and the ABOYA-119 ATR inhibitor trial, and the establishment of a recommended Phase 2 dose for ATRN-119. Other 8-Ks describe private placement financing and the extension of projected cash runway.
Investors can also use the filings feed to monitor how Aprea discusses its lead programs, APR-1051 and ATRN-119, in official documents, including descriptions of trial objectives, biomarker-defined patient populations, and risk factor language incorporated by reference in periodic reports. While this page focuses on real-time access to filings such as 8-Ks, users can also locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or prospectus supplements that relate to equity offerings mentioned in company news.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical milestones, financial condition, and strategic shifts like pausing monotherapy enrollment to consider combination therapies. The platform also surfaces new filings as they are posted to EDGAR, allowing close tracking of Aprea’s regulatory and disclosure history over time.
Aprea Therapeutics disclosure: reporting persons report beneficial ownership of 1,186,294 shares (9.9% of the class). The filing states the total includes 170,753 common shares issuable upon exercise of warrants and excludes 10,155,621 warrants that are not currently exercisable due to beneficial ownership limitations. The filing attributes sole voting power for 1,015,541 shares and sole dispositive power for 1,186,294 shares to the reporting persons, which are AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman.
Aprea Therapeutics, Inc. has filed a shelf registration on Form S-3 to register 74,349,426 shares of Common Stock for resale by selling stockholders. The shares represent up to 37,174,713 shares underlying pre-funded warrants and up to 37,174,713 shares underlying common warrants issued in a private placement closed March 31, 2026. The company will not receive proceeds from resales but will receive cash if warrants are exercised for cash. The registration includes customary beneficial ownership blockers (4.99% or, if elected, 9.99%).
The prospectus also summarizes clinical-stage programs: WEE1 inhibitor APR-1051 (dose escalation up to 220 mg cohort; two unconfirmed partial responses reported), ATR inhibitor ATRN-119 with an RP2D of 1,100 mg once daily, and an early-stage DYRK1 program with IND-enabling studies planned in Q4 2026. Shares outstanding were 11,982,776 as of March 31, 2026.
Aprea Therapeutics, Inc. filed a proxy statement soliciting votes for its 2026 virtual Annual Meeting to be held June 16, 2026, including election of three Class I directors and ratification of EisnerAmper LLP as auditor. The proxy also seeks approval to amend the Certificate of Incorporation to permit a reverse stock split at a ratio between one‑for‑three and one‑for‑eight, with the exact ratio and timing to be set by the Board in its sole discretion.
The record date for voting is April 21, 2026, and the filing discloses 12,382,776 shares outstanding as of April 21, 2026. The Board recommends FOR all named proposals and explains that the reverse split is intended principally to attempt to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.
Aprea Therapeutics reports that Squadron Master Fund LP and related investment adviser Squadron Capital Management, LLC collectively hold 1,271,081 shares of Common Stock via warrants, representing 9.99% of the class. The filing states 11,452,452 shares of Common Stock outstanding as of March 16, 2026.
The statement attributes shared voting and dispositive power over 1,271,081 shares to Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank. The filing includes a Rule 13d-4 disclaimer of beneficial ownership by the adviser and the named partners.
Aprea Therapeutics, Inc. ownership disclosure: a group of Soleus-related entities and Guy Levy report shared beneficial ownership of 1,271,080 shares of Common Stock, representing 9.99% of the class. The percentage is calculated using 11,452,452 shares outstanding as of March 16, 2026.
The reported shares consist of Common Stock issuable upon exercise of pre-funded warrants and common warrants held by Soleus funds; multiple Soleus entities disclaim beneficial ownership except for Section 13(d) purposes.
Aprea Therapeutics SrVP/CFO John P. Hamill bought warrants linked to 61,956 shares of common stock in a private placement. On March 31, 2026, he acquired 30,978 pre-funded warrants at $0.808 per warrant less a $0.001 exercise price and 30,978 accompanying common warrants with a $0.683 exercise price. The warrants are immediately exercisable but subject to a Beneficial Ownership Limitation that prevents exercises above 4.99% ownership of common stock or 9.99% of combined voting power.
Aprea Therapeutics director Richard Peters bought derivative securities linked to the company’s common stock. On March 31, 2026, he acquired pre-funded warrants to purchase 123,915 shares of common stock in a private placement, at a purchase price of $0.808 per pre-funded warrant, less the $0.001 exercise price. He also received accompanying common warrants to purchase up to 123,915 additional shares of common stock, with a $0.683 exercise price per share. Both the pre-funded and common warrants are immediately exercisable, but their exercise is limited by a “Beneficial Ownership Limitation” that generally caps common stock ownership at 4.99% of outstanding shares or 9.99% of aggregate voting power. The common warrants will expire on the earlier of December 31, 2029, or 30 calendar days after exercise of the related pre-funded warrants, proportional to the exercised amount.
Aprea Therapeutics, Inc. closed an oversubscribed private placement, raising total gross proceeds of approximately $30 million. The funding comes from a group led by Soleus Capital, with new and existing investors and certain insiders participating.
The company issued pre-funded warrants to purchase up to about 37.2 million shares of common stock and additional warrants to purchase up to about 37.2 million shares. Warrant exercise prices range around $0.808 and $0.683 per share. Aprea plans to use net proceeds for general corporate purposes and to advance development of its lead WEE1 inhibitor APR-1051, including expanding its ACESOT-1051 study into selected biomarker-defined tumor populations.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for an oversubscribed private placement expected to raise approximately $30 million in gross proceeds through pre-funded warrants and common stock warrants for up to about 37.2 million shares each. The warrants are priced at a purchase price of $0.808 per pre-funded warrant, with a common warrant exercise price of $0.683 per share. Aprea plans to use the upfront net proceeds for general corporate purposes and research and development and currently expects this funding to extend its cash runway into the first quarter of 2028. The company also reported a confirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer, along with additional stable disease cases, supporting early signs of anti-tumor activity.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for an oversubscribed private placement expected to raise approximately $30 million in gross proceeds through pre-funded warrants and common stock warrants for up to about 37.2 million shares each. The warrants are priced at a purchase price of $0.808 per pre-funded warrant, with a common warrant exercise price of $0.683 per share. Aprea plans to use the upfront net proceeds for general corporate purposes and research and development and currently expects this funding to extend its cash runway into the first quarter of 2028. The company also reported a confirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer, along with additional stable disease cases, supporting early signs of anti-tumor activity.